Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...

Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic ...

Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy ...

"[Urologists] really need to understand how big the prostate is and how big of a surgery that they're looking at," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her perspective ...

On January 28, 2025, and February 25, 2025, Urology Times conducted case-based roundtable discussions on the topic of upper tract urothelial cancer (UTUC). The programs were moderated by Katie S.

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...

Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA ...

ABO-101 received orphan drug and rare pediatric disease designations for PH1, targeting the HAO1 gene to reduce oxalate production. Ibex Prostate Detect, an AI-powered diagnostic tool, achieved 510(k) ...

Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, ...

“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's ...